RafarmaPharmaceuticals, Inc. announced that RAFA is in active meetings the City Scientific University of Istanbul (Turkey) to establish a nuclear medicine and proton therapy center at the university. In developed countries, up to 70% of cancer patients undergo proton therapy annually and Rafarma received presentations from Modern Nuclear Technologies LLC on the trends and advantages of this therapy in the treatment of malignant tumors. Proton therapy precisely targets even the most difficult to treat tumors and allows higher doses of radiation to be delivered with fewer side effects. Unlike treatment with conventional X-ray therapy, treatment with proton therapy can be achieved using fewer radiation beams, and is non-invasive. Rafarma is looking to lead the industry in the development of multiple proton therapy centers, with many more projects in the pipeline.